Please login to the form below

Not currently logged in

FDA deems GSK anaemia drug a 'breakthrough'

US regulator will accelerate review of Promacta
FDA headquarters White Oak

GlaxoSmithKline (GSK) has won 'breakthrough' status in the US for the use of Promacta to treat people with a low number of blood cells due to anaemia.

The status, which is granted by the Food and Drug Administration (FDA), specifically covers use of the drug to treat cytopaenias in patients with severe aplastic aneamia (SAA) who have had insufficient response to immunosuppressive therapy.

Breakthrough status is the newest regulatory designation created by the FDA to speed up the approval process for significant new medicines, having been enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA).

Promacta (eltrombopag) fits into this category as it is intended for use in the treatment of a serious medical condition and has already demonstrated it may have a substantial improvement over current therapies.

With this status, GSK can expect an expedited review process for the drug, as per the FDA's Fast Track programme, as well as more intensive guidance from the regulator.

To support its application GSK used data from a phase II study involving the National Institute of Health (NIH) which investigated the use of Promacta in 43 patients with SAA – a rare condition in which the bone marrow fails to make enough new blood cells.

All these patients had been heavily pre-treated but still showed an insufficient response to immunosuppressive therapy. However, Promacta was able to demonstrate a response in these patients, leading to the FDA's decision.

If approved, this would be Promacta's third approval in the US following recommendations in the treatment of low blood cell counts in adults with one of two conditions: chronic hepatitis C before and during treatment with interferon, or chronic immune thrombocytopaenia when certain treatments have not worked.

GSK developed the drug with partners Ligand, which receives royalties on Promacta sales. Outside the US, the drug is known as Revolade.

Article by
Thomas Meek

6th February 2014

From: Sales



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...